SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Barbara Jordan — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBarbara Jordan
Date of birth1936-02-21
IdentifiersMRN HR-ML030-SYN-TD; SSN (made up) 000-30-6852
Document date1980-03-16
AuthorEvangeline Moss, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review with MRI of the brain and spine, seen the same day by multiple sclerosis neurology. [S]

History of Present Illness

Ms. Jordan returns two weeks after her first visit, after MRI of the brain and spine this morning, and is seen by Dr. Watanabe of multiple sclerosis neurology on the same day. Her walking is unchanged: she uses her cane on campus and rests after about 100 meters. She has had no new symptoms and no symptom that came on over days. Her legs are stiff in the mornings. She still gets up twice a night to pass urine and sometimes has to hurry. She has started vitamin D3. The records of her original evaluation have not arrived. She asked about treatments that might slow the disease and how often she would need to be away from work for them. [S]

ElementDetail
WalkingCane on campus; rests after about 100 meters; unchanged
New symptomsNone
BladderUrgency; up twice a night
ImagingMRI of the brain and cervical and thoracic spine with gadolinium this morning

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by mid-afternoon; no fever
EyesNegativeNo blurred or double vision
GenitourinaryPositiveUrgency and nocturia twice; no burning
MusculoskeletalPositiveLeg stiffness in the mornings
NeurologicalPositiveSlowly worsening walking; no new numbness or weakness
PsychiatricNegativeMood steady

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule dailyOne capsule dailyOral route1980-03-02activeS
Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once toleratedOne tablet three times a dayOral route1980-03-16 to 1980-04-20completedS
Mirabegron 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route1980-03-16activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1980-03-16Body height173cmS
1980-03-16Body weight84.2kgS
1980-03-16Body mass index (BMI) [Ratio]28.1kg/m2S
1980-03-16Systolic blood pressure122mm[Hg]S
1980-03-16Diastolic blood pressure76mm[Hg]S
1980-03-16Heart rate74/minS
1980-03-16Respiratory rate16/minS
1980-03-16Body temperature36.6CelS
1980-03-16Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1980-03-16; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/76, pulse 74
NeurologicalSpastic paraparetic gait with a cane in the right hand; hip flexor strength 4 out of 5 on both sides; modified Ashworth 2 in both legs; brisk leg reflexes with extensor plantar responses; reduced vibration sense at the toes; EDSS 6.0; timed 25-foot walk 11.0 seconds
EyesVisual acuity 20/20 in each eye; no relative afferent pupillary defect

Problems

ProblemClinical statusVerificationCodeProvenance
Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spineresolvedconfirmed G35.DS — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts.
Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 1971 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosisactiveconfirmed G35.B1S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts.
Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of fallsactiveconfirmed R26.89S — Synthetic modern coding anchored to her documented cane.
Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residualactiveconfirmed N31.9S — Synthetic; common in multiple sclerosis. No public source describes her bladder.
Vitamin D deficiencyactiveconfirmed E55.9S — Synthetic laboratory finding at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationNew or worsening symptoms (relapse, pseudo-relapse with heat or infection)Every visitCompleted todayNo new symptoms; relapse and pseudo-relapse plan explained with a written card
ExaminationDisability: EDSS and timed 25-foot walkEvery visit, and at least every 6 monthsCompleted todayEDSS 6.0; timed 25-foot walk 11.0 seconds
ImagingBrain MRIAt diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadoliniumCompleted todayDiagnostic MRI with gadolinium: fourteen T2 lesions in characteristic regions; one enhancing lesion
ImagingSpinal cord MRIAt diagnosis; later only for new spinal symptoms or diagnostic doubtCompleted todayThree cord lesions; no compression
LaboratoryHepatitis B surface antigen, core antibody and surface antibodyBefore the first doseUp to dateAll negative at intake: not infected, not immune; vaccination started today
LaboratoryQuantitative immunoglobulinsBefore the first dose, then before each doseUp to dateIgG 1080, IgM 110, IgA 210 mg/dL at intake
LaboratoryBlood count with absolute lymphocytesBefore the first dose, then before each doseUp to dateWhite cells 6.4, lymphocytes 1.9 at intake
LaboratoryLiver testsBefore the first dose, then with symptoms and before each doseUp to dateNormal at intake
LaboratoryVaricella and measles immunity, tuberculosis blood test, HIV, hepatitis C, JC virus antibodyBefore the first doseUp to dateVaricella and measles immune; tuberculosis blood test, HIV and hepatitis C negative; JC virus antibody index 0.14
Medication safetyVaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2)Inactivated at least 2 weeks and live at least 4 weeks before the first doseCompleted todayPCV20, zoster dose 1, Tdap and hepatitis B dose 1 today; no live vaccine needed
ExaminationSpasticity (modified Ashworth) and baclofen toleranceEvery visitCompleted todayModified Ashworth 2 in both legs; baclofen started
ExaminationBladder: urgency, nocturia, urinary infection, and blood pressure on mirabegronEvery visitCompleted todayUrgency and nocturia twice; post-void residual 40 mL at intake; mirabegron started; blood pressure 122/76
ReferralFalls, walking aids and physical therapyEvery visitOrderedNo falls; physical therapy evaluation requested at intake, first appointment awaited
Self-managementFatigue and heat sensitivityEvery visitCompleted todayTires by mid-afternoon; pacing and cooling advice given
Laboratory25-hydroxyvitamin DAt baseline, 8 to 12 weeks after repletion, then yearlyUp to date17 ng/mL at intake; vitamin D3 started at intake
SurveyDepression screen (PHQ-9)At intake, then every 6 months and with any changeUp to datePHQ-9 6 at intake, mostly fatigue and sleep items
Self-managementWorkplace accommodationAt intake and with any changeCompleted todayLetter describing her functional needs, without the diagnosis, given to her to send as she chooses
ReferralMultiple sclerosis neurology reviewAt diagnosis, then every 6 months on therapyCompleted todaySeen by Dr. Watanabe today

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap); Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]

Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Review in five weeks for the second vaccine doses and baclofen titration; first ocrelizumab infusion to be booked at least two weeks after that visit. Same-day call for new or worsening symptoms lasting more than 24 hours. Next scheduled visit 1980-04-20: five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion. [S]